Minimally invasive surgery (MIS) refers to laparoscopic surgery and robotic surgery. These two types of surgery are different based on the tools used during the procedure. The surgeon will either use robotics or laparoscope tools. Surgeons will usually recommend a laparoscopic or robotic procedure based on their own experience and preference.
Minimally invasive surgeries are much more common now because this type of surgery can offer colorectal cancer patients a less painful way to remove part of the colon or the entire colon, create an ostomy, or reconnect and reconstruct the colon.
Minimally invasive surgery can also be used, in some cases, to remove rectal tumors.
Many studies have shown that these surgeries are just as safe as open surgery but they make recovery faster and easier.
Most patients can undergo minimally invasive surgery, such as those with:
- Early stage cancer
- Less advanced cancer
- No prior major surgeries
- Fewer radiation treatments
- Lower Body Mass Index (BMI)
Open surgery might still be recommended for patients with:
- Spread of cancer
- Metastases (additional growths)
- Need to remove the tumor completely
- History of medical conditions
- Higher Body Mass Index (BMI) or obesity
Talk to your doctor to find out if minimally invasive surgery is an option for you.
Michelle Cappel owes a lot to colorectal cancer biomarker testing — seven years of life and counting.
Don Shippey was 55 years old in 2016 when he decided he’d been putting off his colonoscopy long enough.
Takeda has announced U.S. Food and Drug Administration (FDA) approval of FRUZAQLA (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.